Where next for GSK's share price after its latest announcement?
GlaxoSmithKline shares rose 2% last Wednesday after it unveiled plans to split out its consumer health business with a separate listing.
June 28, 2021

This article was originally published on Opto - Where next for GSK's share price after the demerger and dividend cut announcement?

The remaining 'New GSK' will incorporate the pharmaceutical and vaccine business, which will receive a payment of up to PS8bn from the consumer health arm and take on a higher share of the debt, reports Seeking Alpha. In a statement, GSK said the new unit "will be a growth company with new ambitions for patients and shareholders and an overarching purpose to unite science, talent and technology to get ahead of disease together."

The bad news for shareholders is that the dividend will be cut, which will enable more cash to be focused on research and development, although shareholders will receive some of the proceeds of the demerger, reports CMC Markets' Michael Hewson.

GSK share price fails to ride vaccine wave

The GSK share price is up 2.7% so far in 2021, as of Friday 25 June's close of 1,413.20p, though the FTSE 100 constituent has jumped 18.68% from its 52-week low of 1,190.80p on 26 February. Looking back, before the Covid-19 pandemic struck, GSK's share price reached a closing high of 1,846.00p on 17 January 2020. Since that high point, the shares have fallen 23.44%, as GSK failed to enjoy the 'vaccine bounce' seen in other leading drug stocks.

Will the dividend cut hit GSK's share price?

GSK will reduce its dividend for the remaining 'New GSK' business by about 30% next year, in what will be a first dividend payout decline in 20 years, reports Bloomberg. With the current dividend a big attraction for income-seeking investors, the proposed cut could affect investor sentiment in the near term, and potentially lead to additional pressure on the GSK share price. According to CNBC's Jim Cramer, the combined dividend per share from the two new units will be cut by around a third to 55p in 2022, before the 'New GSK' dividend is expected to start at 45p in 2023.

Previewing last week's two-day investor meeting, Cramer said: "If the rumors are true and GlaxoSmithKline really takes a meat-axe to its dividend, then I think you need to be prepared for the stock to get slammed as income-oriented investors dump it." However, he added that, "after it sells off, you could get a good buying opportunity."

Cramer argues that Walmsley has "misjudged her shareholder base. There are a lot of people who own big pharma stocks for the income; the last thing they want is a dividend cut." Time will tell whether this prediction has legs.

What's next for the GSK share price?

The planned dividend reduction is actually "a smaller cut than analysts expected", according to Bloomberg's Suzi Ring, who add that "some investors were also cheered" by the five-year sales growth targets of above 5% a year and profit growth of at least 10% a year through to 2026.

"This updated strategy moves the needle at GSK, from a focus on restructuring to a story driven by growth," said Mike Fox, GSK shareholder and senior fund manager at Royal London Asset Management, reports Bloomberg, adding that "the targets show that management are prepared to be accountable for this growth."

This updated strategy moves the needle at GSK, from a focus on restructuring to a story driven by growth" - Mike Fox

Not everyone is convinced that GSK has the management team in place to take the new company forward, however. The Motley Fool's Cliff D'Arcy says: "setting bold, ambitious targets is one thing, but hitting them requires the right leadership team." He points out that, "under Walmsley's four-year reign since April 2017, the shares are actually down 250p (15%), while rival pharma stocks have boomed."

Looking ahead, Wall Street analysts have an average 12-month price target on the GSK share price of 1 539.13p, according to MarketBeat, which represents an 8.70% gain from Friday's closing price of 1,413.20p. There are currently six Buy, 10 Hold and two sell ratings on the stock, for an overall consensus rating of Hold.

MyWallSt operates a full disclosure policy. MyWallSt staff currently holds long positions in companies mentioned above. Read our full disclosure policy here

Disclaimer Past performance is not a reliable indicator of future results.

CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.

CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.

The Home of Successful Investing.

© 2023 MyWallSt Ltd. All rights reserved.







This website is operated by MyWallSt Ltd (“MyWallSt”). MyWallSt is a publisher and a technology platform, not a registered broker-dealer or registered investment adviser, and does not provide investment advice. All information provided by MyWallSt Limited is of a general nature for information and education purposes, and you should not construe any such information as investment advice. MyWallSt Limited does not take your specific needs, investment objectives or financial situation into consideration, and any investments mentioned may not be suitable for you. You should always carry out your own independent verification of facts and data before making any investment decisions, as we cannot guarantee the accuracy or completeness of any information we publish and any opinions that we publish may be wrong and may change at any time without notice. If you are unsure of any investment decision you should seek a professional financial advisor. MyWallSt Limited is not a registered investment adviser and we do not provide regulated investment advice or recommendations. MyWallSt Limited is not regulated by the Central Bank of Ireland. MyWallSt Limited may provide hyperlinks to web sites operated by third parties. Your use of third party web sites and content, including without limitation, your use of any information, data, advertising, products, or other materials on or available through such web sites, is at your own risk and is subject to the third parties' terms of use.